Particularly challenging in this context is a retrospective, biological analysis of tumor samples from head and neck cancer patients showing that variable expression of EPO-R on tumor cells could be associated with a detrimental clinical outcome in patients treated with r-EPO [26]. This evidence concerns the gene EPOR and neoplasm.